Adenocarcinoma, Bronchiolo-Alveolar  >>  Votrient (pazopanib)  >>  Phase 3
Welcome,         Profile    Billing    Logout  

1 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Votrient (pazopanib) / Novartis, BeiGene
NCT01208064 / 2010-018566-23: Pazopanib Hydrochloride or a Placebo in Treating Patients With Non-Small Cell Lung Cancer Who Have Received First-Line Chemotherapy

Checkmark 2nd line NSCLC
Jun 2015 - Jun 2015: 2nd line NSCLC
Checkmark ESMO 2014
Sep 2014 - Sep 2014: ESMO 2014
Terminated
3
102
Europe, RoW
pazopanib hydrochloride, laboratory biomarker analysis, pharmacogenomic studies, pharmacological study, quality-of-life assessment
European Organisation for Research and Treatment of Cancer - EORTC
Lung Cancer
06/15
06/15

Download Options